phase readout
saveNCT04964934: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
ACTIVE_NOT_RECRUITINGupdated 1d ago
community read0 votes
Sponsor: AstraZeneca. Phase: PHASE3. Conditions: ER-Positive HER2-Negative Breast Cancer
view source ↗
comments(0)
5-min edit window · permanent after that